Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Sparing-effect Placebo Controlled, With Cross-over Study to Evaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Sparing-effect Placebo Controlled, With Cross-over Study to Evaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol/palmitoylethanolamide (Primary) ; Cannabidiol
  • Indications Pervasive child development disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors SciSparc

    • Most Recent Events

    • 31 Dec 2024 According to a SciSparc media release, the company is expected to generate valuable data to advance treatment options for individuals with ASD.
    • 31 Dec 2024 According to a SciSparc media release, the company announced the renewal of its approval from the Israeli Medical Cannabis Agency (IMCA) at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children with autism spectrum disorder.
    • 19 Aug 2024 According to SciSparc media release, the company announced that the first five patients have been enrolled and dosed in this trial at the Soroka Medical Center in Israel.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top